Atsushi Ohtsu Selected Research

Irinotecan (Camptosar)

1/2017	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
10/2015	Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
7/2015	Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
5/2014	Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
1/2014	Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
10/2013	Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
9/2013	Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
8/2013	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
12/2012	Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
10/2012	Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsushi Ohtsu Research Topics

Disease

117	Neoplasms (Cancer) 01/2022 - 08/2000
79	Stomach Neoplasms (Stomach Cancer) 10/2021 - 08/2000
50	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 01/2003
21	Adenocarcinoma 10/2021 - 12/2004
21	Neutropenia 10/2018 - 06/2004
18	Esophageal Neoplasms (Esophageal Cancer) 10/2021 - 01/2002
18	Esophageal Squamous Cell Carcinoma 10/2021 - 06/2006
16	Disease Progression 05/2020 - 09/2000
14	Neoplasm Metastasis (Metastasis) 06/2017 - 08/2000
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2017 - 05/2002
9	Colonic Neoplasms (Colon Cancer) 10/2022 - 02/2011
9	Nausea 01/2018 - 06/2008
8	Carcinoma (Carcinomatosis) 01/2017 - 05/2002
7	Febrile Neutropenia 03/2018 - 02/2008
7	Leukopenia 03/2018 - 02/2008
7	Diarrhea 07/2016 - 06/2004
6	Anorexia 01/2018 - 04/2009
6	Pathologic Constriction (Stenosis) 01/2018 - 05/2002
5	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2006
5	Fatigue 01/2018 - 02/2013
5	Vomiting 01/2017 - 06/2008
5	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 02/2013 - 08/2003
4	Proteinuria 10/2020 - 01/2009
4	Hyperglycemia 08/2015 - 10/2012
4	Squamous Cell Carcinoma of Head and Neck 10/2012 - 10/2002
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2021 - 01/2017
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 11/2021 - 08/2003
3	Hypertension (High Blood Pressure) 03/2018 - 10/2014
3	Ascites 01/2018 - 06/2004
3	Hemorrhage 01/2018 - 04/2002
3	Thrombocytopenia (Thrombopenia) 01/2017 - 06/2015
3	Deglutition Disorders (Dysphagia) 10/2012 - 05/2002
3	Anemia 10/2011 - 06/2004
2	Pleural Effusion (Pleural Effusions) 10/2020 - 06/2009

Drug/Important Bio-Agent (IBA)

41	Fluorouracil (Carac)FDA LinkGeneric 10/2022 - 08/2000
34	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 08/2000
28	Cisplatin (Platino)FDA LinkGeneric 05/2021 - 09/2000
21	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2002
16	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2022 - 08/2003
14	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 08/2000
13	RamucirumabIBA 01/2021 - 10/2014
13	trifluridine tipiracil drug combinationIBA 12/2018 - 10/2012
12	Pharmaceutical PreparationsIBA 06/2021 - 01/2002
11	Trastuzumab (Herceptin)FDA Link 11/2021 - 08/2010
11	Monoclonal AntibodiesIBA 10/2019 - 01/2006
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020 - 01/2002
9	Leucovorin (Folinic Acid)FDA Link 10/2022 - 04/2006
9	PlatinumIBA 10/2021 - 01/2009
7	Bevacizumab (Avastin)FDA Link 05/2018 - 10/2010
7	ErbB Receptors (EGF Receptor)IBA 01/2016 - 01/2002
7	Formaldehyde (Formol)FDA Link 01/2016 - 01/2002
6	Capecitabine (Xeloda)FDA Link 10/2022 - 10/2011
6	human ERBB2 proteinIBA 11/2021 - 08/2010
6	Cetuximab (Erbitux)FDA Link 05/2021 - 06/2009
6	ParaffinIBA 01/2016 - 01/2006
5	pembrolizumabIBA 01/2022 - 01/2018
5	NivolumabIBA 10/2021 - 01/2017
5	S-1 plus cisplatinIBA 05/2021 - 02/2011
5	Proteins (Proteins, Gene)FDA Link 12/2018 - 01/2006
5	Everolimus FDA Link 01/2017 - 01/2010
5	Methotrexate (Mexate)FDA LinkGeneric 10/2013 - 08/2000
5	Imatinib Mesylate (Gleevec)FDA Link 02/2013 - 08/2003
5	Thymidylate SynthaseIBA 01/2011 - 01/2002
4	AntibodiesIBA 11/2017 - 01/2011
4	regorafenibIBA 01/2017 - 06/2015
4	Docetaxel (Taxotere)FDA Link 07/2016 - 01/2002
4	Mitomycin (Mitomycin-C)FDA LinkGeneric 09/2012 - 01/2003
3	pertuzumabIBA 11/2021 - 10/2018
3	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 01/2011
3	Ado-Trastuzumab EmtansineIBA 01/2019 - 10/2016
3	taxaneIBA 01/2019 - 01/2017
3	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 08/2000
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2016 - 02/2015
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 06/2016 - 09/2012
3	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 10/2015 - 01/2002
3	Tyrosine Kinase InhibitorsIBA 10/2015 - 09/2006
3	Insulin (Novolin)FDA Link 08/2015 - 09/2013
3	TOR Serine-Threonine KinasesIBA 11/2013 - 04/2010
3	Sunitinib (Sutent)FDA Link 03/2012 - 12/2010
3	TegafurIBA 11/2009 - 01/2003
3	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2005 - 08/2000
3	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 04/2005 - 01/2002
2	Circulating Tumor DNAIBA 11/2021 - 12/2020
2	afliberceptIBA 10/2020 - 08/2013
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 04/2015
2	B7-H1 AntigenIBA 01/2019 - 10/2018
2	Thymidine PhosphorylaseIBA 01/2018 - 01/2004

Therapy/Procedure

76	Drug Therapy (Chemotherapy) 10/2021 - 09/2000
65	Therapeutics 10/2022 - 08/2000
34	Chemoradiotherapy 06/2017 - 01/2002
8	Radiotherapy 04/2011 - 04/2003
6	Adjuvant Chemotherapy 11/2019 - 09/2000
5	Salvage Therapy 06/2016 - 07/2003
4	Neoadjuvant Therapy 06/2017 - 01/2003
4	Photochemotherapy (Photodynamic Therapy) 06/2016 - 07/2005
3	Induction Chemotherapy 07/2016 - 02/2008
3	Combination Drug Therapy (Combination Chemotherapy) 12/2013 - 02/2006
3	Esophagectomy 10/2012 - 07/2003
3	Endoscopes 10/2012 - 02/2003
3	Gastrectomy 06/2005 - 09/2000